Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
Evommune, Inc. (
NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
